Close Menu
    What's Hot

    The Royal Society of Chemistry Pension Scheme Completes Bulk Purchase Annuity Buy-in With PIC

    August 13, 2026

    US Individual Life Insurance Sales Continue Growth Trend in the Second Quarter

    August 13, 2026

    Editor’s Letter – Volume 2, Issue 8, August 2026

    August 12, 2026
    X (Twitter) LinkedIn
    Longevity & Mortality Investor
    • Home
    • Coverage
      1. Life Insurance Capital Solutions
      2. Life Insurance
      3. Longevity and Mortality Risk Transfer
      4. Mortality
      5. Secondary Life Markets
      6. View All

      Lincoln Financial Reinsures Universal Life Block With Talcott

      August 3, 2026

      US Annuity Sales Set New Quarterly Record in Second Quarter

      August 3, 2026

      Big Year of Growth for Life/Annuity Sidecar-Like Activity in 2025

      July 2, 2026

      Sixth Street To Become Majority Shareholder of Monument Re

      June 30, 2026

      US Individual Life Insurance Sales Continue Growth Trend in the Second Quarter

      August 13, 2026

      Shaping the Future of Health Insurance Through Innovation and Analytics

      June 10, 2026

      Q&A: Dr Christoph Schmitt, Director, Insurance, Fitch Ratings

      May 28, 2026

      Chronic Disease Onset and Cumulative Exposure: Clinical, Prognostic and Underwriting Implications

      May 13, 2026

      US Life Carriers Eyeing VM-22 for a Pension Risk Transfer Pricing Advantage in 2027

      August 12, 2026

      Elementis Group Pension Scheme Completes Bulk Purchase Annuity Buy-In With Aviva

      August 5, 2026

      Hickson UK Group Pension Scheme Completes Bulk Purchase Annuity Transaction With Royal London

      August 3, 2026

      UK Insurance Company Pension Scheme Completes Bulk Purchase Annuity Transaction With M&G

      August 3, 2026

      Record Low Mortality Rates So Far in England and Wales in 2026

      July 9, 2026

      Organ Transplant Improvements Test Life Expectancy Assessment Models

      July 8, 2026

      The Pursuit of Everlasting Life Unlikely to Shift Actuarial Models

      June 10, 2026

      Pricing in the Unknown: Why Mortality Models Aren’t Ready for MCED Tests Just Yet

      April 9, 2026

      The Royal Society of Chemistry Pension Scheme Completes Bulk Purchase Annuity Buy-in With PIC

      August 13, 2026

      New Life Settlement Provider Data Illustrates Continued Evolution of Secondary Life Settlement Market

      August 12, 2026

      The Crucial Role of Regular Medical Record Reviews in Life Settlement Investments

      August 12, 2026

      Corry Capital Advisors Adds John Daniel as Senior Director of Analytics and AI Strategy

      August 6, 2026

      The Royal Society of Chemistry Pension Scheme Completes Bulk Purchase Annuity Buy-in With PIC

      August 13, 2026

      US Individual Life Insurance Sales Continue Growth Trend in the Second Quarter

      August 13, 2026

      Editor’s Letter – Volume 2, Issue 8, August 2026

      August 12, 2026

      New Life Settlement Provider Data Illustrates Continued Evolution of Secondary Life Settlement Market

      August 12, 2026
    • Events
    • Latest Issues

      Editor’s Letter – Volume 2, Issue 8, August 2026

      August 12, 2026

      Editor’s Letter – Volume 2, Issue 7, July 2026

      July 8, 2026

      Editor’s Letter – Volume 2, Issue 6, June 2026

      June 10, 2026

      Editor’s Letter – Volume 2, Issue 5, May 2026

      May 13, 2026

      Editor’s Letter – Volume 2, Issue 4, April 2026

      April 9, 2026
    • Contact Us
    Newsletter
    Longevity & Mortality Investor

    Breaking the Bottleneck: Why GMP Equalisation and Data Challenges Are Delaying Buyouts in 2025

    Longevity and Mortality Risk Transfer September 10, 2025By Kelvin Wilson
    Share
    Twitter LinkedIn Email

    GMP Equalisation (GMPe) is continuing to be a significant hurdle for DB pension schemes on the final stretch to buyout. 

    As bulk purchase annuity (BPA) transactions continue at pace, we’re seeing first-hand that an increasing bottleneck in a scheme’s journey to buyout is GMPe. Often avoided or deferred during earlier stages of transactions, delays in completing GMPe projects is creating additional uncertainty and costs to schemes and insurers looking to reach buyout. 

    The GMP equalisation logjam in the pension risk transfer market 

    GMP equalisation remains a complex and time-consuming exercise. It involves rectifying historical benefit calculations to ensure male and female members with equivalent service receive equal benefits – a legal requirement that dates back to the Lloyds case rulings in 2018. GMPe is a project involving data analytics, record reviews and non-trivial calculations. If done during a PRT transaction, GMPe is a complex project within an already complex transaction! 

    In recent discussions at industry events, GMPe was widely seen as one of the key factors slowing the path to policy issuance and scheme wind-up. 

    Advisers and insurers alike have pointed to a growing backlog of schemes unable to complete buyout transaction due to unresolved GMPe and related data issues. 

    Regulatory pressure and member expectations 

    As well as affecting scheme administration and governance, delayed GMPe projects has adverse implications for both member outcomes and regulatory compliance. The Pensions Ombudsman’s recent suggestion that schemes should no longer treat GMPe as optional or deferrable points to a shift in attitude. Failure to address GMPe can lead to incorrect benefit values being displayed on member communications or pension dashboards, potentially undermining trust and raising compliance concerns. 

    As value data becomes increasingly visible through the Pensions Dashboards Programme, schemes will need to ensure the benefit information they’re sharing is complete and accurate. That means as well as satisfying insurers and their appetite for risk during bulk-annuity transactions, resolving legacy GMP issues is also about meeting evolving expectations from both members and regulators. 

    Data quality and calculation complexity: the bigger picture 

    Of course, GMPe isn’t the only bottleneck. Across the market, schemes are facing growing pressure to deliver clean, validated data and accurate benefit specifications in formats that meet insurer standards. That includes managing multiple data templates, reconciling historic administration records, and applying complex actuarial factors for early or late retirement. 

    All of this is happening in a high-volume market, where more schemes than ever are transacting and insurer engagement windows are tightening. As a result, schemes that can’t meet the data and benefit requirements in good time risk delays, pricing uncertainty or even being deprioritised. 

    A tech-led approach to beating the bottleneck 

    Fortunately, there are solutions that use technology to enable schemes and advisors to work efficiently. They offer support in specific areas of data cleansing, data mapping and benefit calculations, including GMPe. 

    For example, a rules-based, low-code calculations engine designed to bring automation to and process complex benefit calculations at speed – the perfect antidote for tackling GMPe and other data-heavy calculations. The schemes and their advisors who are applying efficient technology to relevant parts of the bulk annuity and PRT process can benefit from a reduced time required to move from buy-in to buyout. 

    Insurers will also benefit. By reducing ambiguity and administrative friction, schemes can present a clearer, more complete picture of their liabilities, enabling for more accurate pricing and faster engagement, a competitive edge trustees might just be looking for. 

    Working in partnership to resolve GMPe challenges 

    Through considered integration of technology and partnerships, it is possible to relieve the bottleneck described at the start of this article. Technology solutions will support and complement the efforts of incumbent advisers, administrators and trustees. Where schemes lack the capacity or bandwidth to tackle GMPe and data issues internally, bringing in specialist support can accelerate timelines without adding complexity. 

    As demand continues to rise in 2025 and beyond, this collaborative, tech-led approach may prove essential to keeping deals moving, and ensuring schemes are able to secure buyouts when market conditions are most favourable. 

    As the PRT market continues to surge ahead, the need for efficiency at each stage is real, but the barriers to buyout remain stubborn. GMP equalisation, data readiness and benefit specification challenges are now among the biggest factors slowing schemes down. 

    With the right tools, support and technology, these obstacles don’t have to derail transactions. By addressing GMPe early and investing in scalable, efficient data and calculations solutions, schemes can stay ahead of the curve, helping achieve the outcomes their members deserve. 

    Kelvin Wilson is Director, Pension Risk Transfer, at Heywood 


    This article was originally published on heywood.com  

    Any views expressed in this article are those of the author(s) and may not necessarily represent those of Life Risk News or its publisher, the European Life Settlement Association

    2025 - September Commentary Longevity Risk Pension Risk Transfer Volume 4 Issue 9 – September 2025
    Share. Twitter LinkedIn Email

    Related Posts

    US Life Carriers Eyeing VM-22 for a Pension Risk Transfer Pricing Advantage in 2027

    August 12, 2026By Greg Winterton

    Elementis Group Pension Scheme Completes Bulk Purchase Annuity Buy-In With Aviva

    August 5, 2026By LMI Newsdesk

    Hickson UK Group Pension Scheme Completes Bulk Purchase Annuity Transaction With Royal London

    August 3, 2026By LMI Newsdesk

    Lincoln Financial Reinsures Universal Life Block With Talcott

    August 3, 2026By LMI Newsdesk
    Latest Issue

    New Life Settlement Provider Data Illustrates Continued Evolution of Secondary Life Settlement Market

    August 12, 2026

    The Crucial Role of Regular Medical Record Reviews in Life Settlement Investments

    August 12, 2026

    US Life Carriers Eyeing VM-22 for a Pension Risk Transfer Pricing Advantage in 2027

    August 12, 2026

    End-Game Clarity Shaping UK Pension Risk Transfer Market but Large Schemes Still on the Sidelines

    July 22, 2026
    Ad

    Where Longevity and Mortality Meet the Markets
    ISSN 2978-5219

    X (Twitter) LinkedIn
    Coverage
    • Life Insurance Capital Solutions
    • Life Insurance
    • Longevity and Mortality Risk Transfer
    • Mortality Risk
    • Secondary Life Markets
    More Info
    • Home
    • About Us
    • Contact Us
    • Guest Articles
    • Submit Story Idea
    Our Newsletter
    Get the latest industry news, commentary and events from the Longevity & Mortality Investor directly into your inbox. Why not sign up today?

    © 2026 Longevity & Mortality Investor. Website by Kavells.
    • Sitemap
    • Privacy Policy
    • Copyright Notice
    • Terms & Conditions

    Type above and press Enter to search. Press Esc to cancel.